What SEC filings does Viridian Therapeutics, Inc. submit to the SEC?

Viridian Therapeutics, Inc. (VRDN) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about VRDN?

A Form 4 for VRDN discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Viridian Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for VRDN?

The 10-K is Viridian Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all VRDN SEC filings directly on EDGAR?

You can view all historical Viridian Therapeutics, Inc. filings on the SEC EDGAR company page for VRDN. Each filing card on this page links directly to the original SEC document.

How often does Viridian Therapeutics, Inc. file with the SEC?

Viridian Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling VRDN shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

VRDN SEC Filing News — Viridian Therapeutics, Inc.

Latest SEC filings for Viridian Therapeutics, Inc. (VRDN) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-20.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease…

Sector: Healthcare Industry: Biotechnology Market Cap: $2.4B CIK: 1590750

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

What you're looking at: Each item below is parsed from an actual SEC filing submitted by Viridian Therapeutics, Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.

VRDN Filing Activity Snapshot 2026-05-05 — 2026-08-20

Insider Transactions (Form 4)

1 buy vs 1 sell

Insider buying and selling activity is balanced in this period.

Largest Form 144 Filing

$20.00M

Fairmount Funds Management LLC (Director, 10% Owner) · 2026-05-13

1,176,470 shares · Form 4

Form 144 Notices

Proposed insider sale filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for Viridian Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 6 compensation award, 1 option exercise, 1 open-market purchase and 1 open-market sale. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Option exercise ×1: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Open-market sale ×1: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-08-20

VRDN insider Tousignant Jennifer (Chief Legal Officer) sold 14,212 shares (~$348.2K)

Tousignant Jennifer, listed as Chief Legal Officer at Viridian Therapeutics, Inc.\DE, reported an open-market sale of 14,212 VRDN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	4,212	$24.50	$103.2K
`M`	Option exercise	10,000	$14.41	$144.1K
`S`	Open-market sale	10,000	$24.50	$245.0K
`M`	Option exercise derivative · Stock Option (Right to Buy)	10,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Tousignant Jennifer (Chief Legal Officer) Shares: 14,212 Est. Value: $348.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-08-18

VRDN insider Form 4 filed for equity award, exercise, or tax withholding

Tripuraneni Radhika (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	40,000	$13.21	$528.4K
`M`	Option exercise derivative · Stock Option (Right to Buy)	40,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Tripuraneni Radhika (Chief Medical Officer) Shares: 40,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-02

VRDN insider Form 4 filed for equity award, exercise, or tax withholding

CAIN CHRISTOPHER W. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	32,341	—	—

Filing: Form 4 (Insider Transaction) Insider: CAIN CHRISTOPHER W. (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-02

VRDN insider Form 4 filed for equity award, exercise, or tax withholding

Ajer Jeffrey Robert (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	32,341	—	—

Filing: Form 4 (Insider Transaction) Insider: Ajer Jeffrey Robert (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-02

VRDN insider Form 4 filed for equity award, exercise, or tax withholding

Moses Jennifer K. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	32,341	—	—

Filing: Form 4 (Insider Transaction) Insider: Moses Jennifer K. (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-02

VRDN insider Form 4 filed for equity award, exercise, or tax withholding

Gheuens Sarah (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	32,341	—	—

Filing: Form 4 (Insider Transaction) Insider: Gheuens Sarah (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-02

VRDN insider Form 4 filed for equity award, exercise, or tax withholding

Kiselak Tomas (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	32,341	—	—

Filing: Form 4 (Insider Transaction) Insider: Kiselak Tomas (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-02

VRDN insider Form 4 filed for equity award, exercise, or tax withholding

Morris Arlene (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	32,341	—	—

Filing: Form 4 (Insider Transaction) Insider: Morris Arlene (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-13

VRDN insider Fairmount Funds Management LLC (Director, 10% Owner) bought 1,176,470 shares (~$20.00M)

Fairmount Funds Management LLC, listed as Director, 10% Owner at Viridian Therapeutics, Inc.\DE, reported an open-market purchase of 1,176,470 VRDN shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,176,470	$17.00	$20.00M

Filing: Form 4 (Insider Transaction) Insider: Fairmount Funds Management LLC (Director, 10% Owner) Shares: 1,176,470 Est. Value: $20.00M

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 1 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Viridian Therapeutics, Inc. has 1 such notice in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-19

VRDN Form 144 filed for proposed insider sale by Tousignant Jennifer (14,212 shares) ~$348.2K

Tousignant Jennifer filed a Form 144 with the SEC indicating intent to sell VRDN (Viridian Therapeutics, Inc.\DE) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Tousignant Jennifer Shares: 14,212 Est. Value: $348.2K

View on SEC EDGAR → Open Filing Document →

Material Events 8 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 8 in this period for Viridian Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-06